Chemomab Therapeutics CMMB
NASDAQ CMMB
$1.03 -0.05 (-4.63%)
As of: Oct 23, 2026 · 3:56 PM EDT

Chemomab Therapeutics (CMMB) Revenue (2018 - 2019)

Updated

Analysis

Chemomab Therapeutics (CMMB) Revenue (2018 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn 22.97 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn 25.40 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn 16.99 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn 16.61 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn 14.41 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn 15.38 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn 10.05 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn 7.80 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn 15.03 Bn
10 Chemomab Therapeutics 6.52 Mn -28.63 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2019 12.45 Mn
Sep 30, 2018 60,000.00
API Access

Chemomab Therapeutics Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=revenue&ticker=CMMB&period=max&api_key=YOUR_API_KEY